These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 16818479)

  • 1. Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer.
    Lee KH; Han SW; Hwang PG; Oh DY; Kim DW; Chung DH; Im SA; Kim TY; Heo DS; Bang YJ
    Jpn J Clin Oncol; 2006 Jun; 36(6):344-50. PubMed ID: 16818479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation.
    Han SW; Kim TY; Jeon YK; Hwang PG; Im SA; Lee KH; Kim JH; Kim DW; Heo DS; Kim NK; Chung DH; Bang YJ
    Clin Cancer Res; 2006 Apr; 12(8):2538-44. PubMed ID: 16638863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to first-line chemotherapy in patients with non-small-cell lung cancer according to epidermal growth factor receptor and K-RAS mutation status.
    Dong X; Zhao X; Hao Y; Wei Y; Yin Q; Du J
    Clin Lung Cancer; 2013 Nov; 14(6):680-7. PubMed ID: 23910066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations.
    Masuda T; Imai H; Kuwako T; Miura Y; Yoshino R; Kaira K; Shimizu K; Sunaga N; Tomizawa Y; Ishihara S; Mogi A; Hisada T; Minato K; Takise A; Saito R; Yamada M
    Clin Transl Oncol; 2015 Sep; 17(9):702-9. PubMed ID: 25990507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).
    Cappuzzo F; Ligorio C; Toschi L; Rossi E; Trisolini R; Paioli D; Magrini E; Finocchiaro G; Bartolini S; Cancellieri A; Hirsch FR; Crino L; Varella-Garcia M
    J Thorac Oncol; 2007 May; 2(5):423-9. PubMed ID: 17473658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer-data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002).
    Miyauchi E; Inoue A; Kobayashi K; Maemondo M; Sugawara S; Oizumi S; Isobe H; Gemma A; Saijo Y; Yoshizawa H; Hagiwara K; Nukiwa T;
    Jpn J Clin Oncol; 2015 Jul; 45(7):670-6. PubMed ID: 25877748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03.
    D'Addario G; Rauch D; Stupp R; Pless M; Stahel R; Mach N; Jost L; Widmer L; Tapia C; Bihl M; Mayer M; Ribi K; Lerch S; Bubendorf L; Betticher DC
    Ann Oncol; 2008 Apr; 19(4):739-45. PubMed ID: 18096565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
    Fukuoka M; Wu YL; Thongprasert S; Sunpaweravong P; Leong SS; Sriuranpong V; Chao TY; Nakagawa K; Chu DT; Saijo N; Duffield EL; Rukazenkov Y; Speake G; Jiang H; Armour AA; To KF; Yang JC; Mok TS
    J Clin Oncol; 2011 Jul; 29(21):2866-74. PubMed ID: 21670455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
    Maemondo M; Inoue A; Kobayashi K; Sugawara S; Oizumi S; Isobe H; Gemma A; Harada M; Yoshizawa H; Kinoshita I; Fujita Y; Okinaga S; Hirano H; Yoshimori K; Harada T; Ogura T; Ando M; Miyazawa H; Tanaka T; Saijo Y; Hagiwara K; Morita S; Nukiwa T;
    N Engl J Med; 2010 Jun; 362(25):2380-8. PubMed ID: 20573926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Molecular targeted therapy--non-small-cell lung cancer and gefitinib].
    Shimizu J; Horio Y; Mitsudomi T
    Gan To Kagaku Ryoho; 2005 Nov; 32(12):1879-85. PubMed ID: 16282720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.
    Han SW; Kim TY; Hwang PG; Jeong S; Kim J; Choi IS; Oh DY; Kim JH; Kim DW; Chung DH; Im SA; Kim YT; Lee JS; Heo DS; Bang YJ; Kim NK
    J Clin Oncol; 2005 Apr; 23(11):2493-501. PubMed ID: 15710947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of epidermal growth factor receptor gene mutations on treatment outcome after first-line cytotoxic chemotherapy in Japanese patients with non-small cell lung cancer.
    Hotta K; Kiura K; Toyooka S; Takigawa N; Soh J; Fujiwara Y; Tabata M; Date H; Tanimoto M
    J Thorac Oncol; 2007 Jul; 2(7):632-7. PubMed ID: 17607119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib.
    Xu JM; Han Y; Duan HQ; Gao EM; Zhang Y; Liu XQ; Zhang JS; Toschi L; Galetta D; Azzariti A; Paradiso A
    J Cancer Res Clin Oncol; 2009 Jun; 135(6):771-82. PubMed ID: 19020901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib.
    Giovannetti E; Zucali PA; Peters GJ; Cortesi F; D'Incecco A; Smit EF; Falcone A; Burgers JA; Santoro A; Danesi R; Giaccone G; Tibaldi C
    Mol Cancer Ther; 2010 Mar; 9(3):581-93. PubMed ID: 20159991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
    Roberts PJ; Stinchcombe TE; Der CJ; Socinski MA
    J Clin Oncol; 2010 Nov; 28(31):4769-77. PubMed ID: 20921461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
    Rosell R; Carcereny E; Gervais R; Vergnenegre A; Massuti B; Felip E; Palmero R; Garcia-Gomez R; Pallares C; Sanchez JM; Porta R; Cobo M; Garrido P; Longo F; Moran T; Insa A; De Marinis F; Corre R; Bover I; Illiano A; Dansin E; de Castro J; Milella M; Reguart N; Altavilla G; Jimenez U; Provencio M; Moreno MA; Terrasa J; Muñoz-Langa J; Valdivia J; Isla D; Domine M; Molinier O; Mazieres J; Baize N; Garcia-Campelo R; Robinet G; Rodriguez-Abreu D; Lopez-Vivanco G; Gebbia V; Ferrera-Delgado L; Bombaron P; Bernabe R; Bearz A; Artal A; Cortesi E; Rolfo C; Sanchez-Ronco M; Drozdowskyj A; Queralt C; de Aguirre I; Ramirez JL; Sanchez JJ; Molina MA; Taron M; Paz-Ares L;
    Lancet Oncol; 2012 Mar; 13(3):239-46. PubMed ID: 22285168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and molecular features in patients with advanced non-small-cell lung carcinoma refractory to first-line platinum-based chemotherapy.
    Giroux Leprieur E; Antoine M; Vieira T; Duruisseaux M; Poulot V; Rabbe N; Belmont L; Gounant V; Lavolé A; Milleron B; Lacave R; Cadranel J; Wislez M
    Lung Cancer; 2013 Feb; 79(2):167-72. PubMed ID: 23153658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic cell growth inhibition by the combination of amrubicin and Akt-suppressing agents in K-ras mutation-harboring lung adenocarcinoma cells: implication of EGFR tyrosine kinase inhibitors.
    Ito S; Igishi T; Takata M; Ueda Y; Matsumoto S; Kodani M; Takeda K; Izumi H; Sakamoto T; Yamaguchi K; Makino H; Touge H; Chikumi H; Shimizu E
    Int J Oncol; 2014 Mar; 44(3):685-92. PubMed ID: 24399305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
    Lynch TJ; Bell DW; Sordella R; Gurubhagavatula S; Okimoto RA; Brannigan BW; Harris PL; Haserlat SM; Supko JG; Haluska FG; Louis DN; Christiani DC; Settleman J; Haber DA
    N Engl J Med; 2004 May; 350(21):2129-39. PubMed ID: 15118073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.